Shares of uniQure BV (NASDAQ:QURE) jumped 36% on Monday after reports that Vinay Prasad, the head of the U.S. Food and Drug Administration’s division of vaccines and gene therapies, will step down next month to return to an academic post. The announcement prompted a wave of analyst activity across the biotech sector, lifting other gene therapy and rare-disease names.
The market reaction extended beyond uniQure. REGENXBIO (NASDAQ:RGNX) climbed 13% and Biohaven (NYSE:BHVN) advanced 23% on the same news, reflecting investor repositioning amid changing expectations about the agency’s approach to gene therapies.
RBC Capital’s Luca Issi moved uniQure from Sector Perform to Outperform and set a new price target of $35.00, up from $11.00. Issi cited the leadership change as a potential catalyst for a "more balanced discussion on risk/reward for HD," and said he now assigns a 50% probability that uniQure’s Huntington’s disease treatment will eventually receive approval.
Stifel analyst Paul Matteis characterized Prasad’s departure as "a big win for biotech, especially for companies in the rare disease space." Matteis noted that a number of gene therapy and rare-disease companies had been grouped into an "FDA risk off" cohort amid regulatory friction, and that Prasad had reportedly overturned some internal review team recommendations to issue negative guidance.
A Truist analyst observed that Prasad’s tenure represented "a sharp departure from the more flexible regulatory approach for rare and serious diseases" that had existed under his predecessor, Peter Marks. Under Prasad’s leadership, several companies faced shifting standards that differed from previously agreed-upon pathways established during development interactions, according to the analyst commentary.
UniQure currently has a Type B meeting with the FDA scheduled for the second quarter. That meeting stands as a formal touchpoint between the company and regulators as the regulatory environment evolves.
Market participants and research firms quickly re-evaluated risk profiles across affected names. RBC Capital’s upgrade on uniQure and the sharp upward moves in peer stocks illustrate how regulatory leadership changes can materially affect near-term sentiment and valuations in gene therapy and rare-disease sectors.
Separately, a research product known as ProPicks AI was mentioned in market commentary as a tool that evaluates QURE alongside thousands of other companies each month using a broad set of financial metrics. The commentary noted that the AI-driven product has identified past winners such as Super Micro Computer (+185%) and AppLovin (+157%), and that it ranks opportunities based on fundamentals, momentum, and valuation.
Summary
Vinay Prasad will leave the FDA division overseeing vaccines and gene therapies next month, prompting uniQure shares to surge 36% and lifting other gene therapy and rare-disease stocks. Analysts upgraded uniQure and adjusted probability of approval for its Huntington’s disease candidate, while market participants reassess regulatory risk for the sector.